ZAGONEL, VITTORINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.397
AS - Asia 2.810
EU - Europa 1.649
AF - Africa 653
SA - Sud America 588
OC - Oceania 72
Continente sconosciuto - Info sul continente non disponibili 32
AN - Antartide 1
Totale 11.202
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.075
SG - Singapore 1.127
CN - Cina 547
BR - Brasile 368
IT - Italia 312
HK - Hong Kong 293
DE - Germania 214
VN - Vietnam 172
FI - Finlandia 144
PL - Polonia 88
GB - Regno Unito 82
FR - Francia 77
NL - Olanda 72
SE - Svezia 65
RU - Federazione Russa 64
BJ - Benin 53
CI - Costa d'Avorio 52
IN - India 52
CA - Canada 48
AT - Austria 42
AR - Argentina 39
TR - Turchia 37
ZA - Sudafrica 37
KR - Corea 36
MX - Messico 33
IQ - Iraq 32
AE - Emirati Arabi Uniti 29
ES - Italia 29
ID - Indonesia 28
EC - Ecuador 27
UA - Ucraina 26
CZ - Repubblica Ceca 25
KE - Kenya 25
PE - Perù 25
ZW - Zimbabwe 25
AO - Angola 23
HU - Ungheria 23
IE - Irlanda 23
PY - Paraguay 23
AL - Albania 22
AZ - Azerbaigian 22
BD - Bangladesh 22
LB - Libano 22
SK - Slovacchia (Repubblica Slovacca) 22
BE - Belgio 21
CL - Cile 21
CO - Colombia 21
DO - Repubblica Dominicana 21
GF - Guiana Francese 21
MD - Moldavia 21
IR - Iran 20
JP - Giappone 20
LA - Repubblica Popolare Democratica del Laos 20
MA - Marocco 20
PS - Palestinian Territory 20
SN - Senegal 20
TW - Taiwan 20
BA - Bosnia-Erzegovina 19
CH - Svizzera 19
CU - Cuba 19
GH - Ghana 19
PK - Pakistan 19
CR - Costa Rica 18
GR - Grecia 18
JO - Giordania 18
UZ - Uzbekistan 18
ZM - Zambia 18
BO - Bolivia 17
BY - Bielorussia 17
JM - Giamaica 17
LU - Lussemburgo 17
ML - Mali 17
NZ - Nuova Zelanda 17
RO - Romania 17
SA - Arabia Saudita 17
VE - Venezuela 17
YE - Yemen 17
AM - Armenia 16
AU - Australia 16
CW - ???statistics.table.value.countryCode.CW??? 16
EG - Egitto 16
GA - Gabon 16
LV - Lettonia 16
TN - Tunisia 16
UG - Uganda 16
CV - Capo Verde 15
ME - Montenegro 15
PF - Polinesia Francese 15
PH - Filippine 15
RS - Serbia 15
TH - Thailandia 15
BS - Bahamas 14
BW - Botswana 14
BZ - Belize 14
DK - Danimarca 14
EE - Estonia 14
GE - Georgia 14
KG - Kirghizistan 14
KH - Cambogia 14
NI - Nicaragua 14
Totale 10.567
Salva come PNG Salva come JPEG
Città #
Ashburn 803
Fairfield 659
Singapore 624
Chandler 490
Cambridge 263
Woodbridge 259
Seattle 253
Houston 227
Hong Kong 223
Wilmington 190
Beijing 180
Ann Arbor 166
Santa Clara 130
Munich 94
Los Angeles 91
San Diego 85
Boardman 84
Helsinki 84
Padova 74
Ho Chi Minh City 65
Medford 58
New York 58
Princeton 58
Bytom 52
Cotonou 52
Abidjan 51
Chicago 46
Des Moines 44
Hefei 41
Hanoi 38
São Paulo 35
Nuremberg 29
Turku 29
Brooklyn 28
Buffalo 27
Warsaw 27
Milan 26
Vienna 25
Seoul 24
Johannesburg 22
Lappeenranta 22
Baku 21
Dallas 21
Harare 21
Nairobi 21
Salt Lake City 21
Dakar 20
Luanda 20
London 19
Amman 18
Dublin 18
Falkenstein 18
Boston 17
Cayenne 17
Lusaka 17
Montreal 17
Havana 16
Kampala 16
Lima 16
Poplar 16
San José 16
Bamako 15
Chennai 15
Libreville 15
Tashkent 15
Accra 14
Auckland 14
Bishkek 14
Council Bluffs 14
Istanbul 14
Nassau 14
Panama City 14
Vientiane 14
Willemstad 14
Denver 13
Phnom Penh 13
Phoenix 13
Podgorica 13
Riga 13
Tbilisi 13
Tokyo 13
Amsterdam 12
Budapest 12
Chisinau 12
Düsseldorf 12
Guangzhou 12
La Paz 12
Managua 12
Minsk 12
Nouakchott 12
Papeete 12
San Francisco 12
Toronto 12
Yerevan 12
Andorra la Vella 11
Castries 11
Conakry 11
Dili 11
Frankfurt am Main 11
Gaborone 11
Totale 6.701
Salva come PNG Salva come JPEG
Nome #
Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up 257
Genetic, epigenetic and immunologic profiling of MMR-deficient relapsed glioblastoma 246
Class 1, 2 and 3 BRAF mutated metastatic colorectal cancer: a detailed clinical, pathological and molecular characterization 245
Letter to Editor: Reply to R.T. Casey (Semin Oncol. 2018 Jun;45(3):151-155) 228
Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials 221
Immune senescence and immune activation in elderly colorectal cancer patients 219
Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study 219
Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor 213
Immunotherapy in Gastrointestinal Cancers 212
CK7 and consensus molecular subtypes as major prognosticators in V600E BRAF mutated metastatic colorectal cancer 211
An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer 206
Anaplastic Astrocytoma: State of the art and future directions 200
Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma 195
mTOR pathway and somatostatin receptors expression intratumor-heterogeneity in ileal NETs 192
Immunotherapy in Gastrointestinal Cancers 189
Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases 188
IMMUNOREACT 5: female patients with rectal cancer have better immune editing mechanisms than male patients, a cohort study 187
Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: A phase II study with pharmacokinetic analysis 186
Multidisciplinary osteoncologic approach to bone metastases: Analysis of a large, mono-institutional cohort 184
Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma 182
Mismatch-repair protein expression in high-grade gliomas: A large retrospective multicenter study 176
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 175
Association of cldn18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas 174
PET/MR in recurrent glioblastoma patients treated with regorafenib: [18F]FET and DWI-ADC for response assessment and survival prediction 173
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 172
Comparison between18F-Dopa and 18F-Fet PET/CT in patients with suspicious recurrent high grade glioma: A literature review and our experience 169
Extraskeletal Myxoid Chondrosarcoma: clinical and molecular characteristics and outcomes of patients treated at two Institutions 165
Clinical management of diffuse low-grade gliomas 164
A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib 164
Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab 161
Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer? 160
Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study 160
Pros-IT CNR: an Italian prostate cancer monitoring project 157
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 157
Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study 156
Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases 154
Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives 151
Discordance of IDH mutational status between lesions in an adult patient with multifocal glioma 149
Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status 148
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 146
An Overview of Intracranial Ependymomas in Adults 145
High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients 144
Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas 143
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial 137
Sustained accumulation of blood‐derived macrophages in the immune microenvironment of patients with recurrent glioblastoma after therapy 137
Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study 136
Suspicious for recurrent low and high grade glioma and indeterminate MRI: the role of 18F-DOPA PET/CT 135
A real-world application of liquid biopsy in metastatic colorectal cancer: The poseidon study 135
Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis 134
Periostin and epithelial-mesenchymal transition score as novel prognostic markers for leiomyosarcoma, myxofibrosarcoma, and undifferentiated pleomorphic sarcoma 133
Phosphorylated acetyl-coa carboxylase is associated with clinical benefit with regorafenib in relapsed glioblastoma: REGOMA trial biomarker analysis 133
Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review 132
Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters 132
Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients 128
Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study 126
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial 126
The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation 125
Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profiling 124
The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors 120
Synaptophysin expression in V600EBRAF-mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis 119
Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E-mutant and SOX2 amplification 114
Bone metastases from neuroendocrine tumors: clinical and biological considerations 112
PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review 109
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: The CARACAS study 106
null 103
The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study 101
Other than restaging phase: serial FCH-PET/CT scans can predict the reponse to chemotherapy (CT) in castrate-resistant prostate cancer (CRPCa)? 100
How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study 99
Advanced Adrenocortical Carcinoma: From Symptoms Control to Palliative Care 95
Trabectedin and Radiation Therapy for Cardiac Metastasis From Leiomyosarcoma: A Case Report and Review of the Literature 87
Trabectedin and Radiation Therapy for Cardiac Metastasis From Leiomyosarcoma: A Case Report and Review of the Literature 82
Impact of Gastrointestinal Side Effects on Patients' Reported Quality of Life Trajectories after Radiotherapy for Prostate Cancer: Data from the Prospective, Observational Pros-IT CNR Study 80
Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study) 69
Totale 11.312
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.900
article - articoli 40.900
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.800
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021456 0 0 0 0 0 23 40 106 70 98 89 30
2021/2022976 54 73 59 54 62 108 109 79 90 30 60 198
2022/2023967 151 120 28 131 93 89 33 63 188 24 36 11
2023/2024592 16 100 70 49 56 95 70 18 17 21 38 42
2024/20252.238 6 125 98 87 205 121 79 219 188 146 415 549
2025/20264.601 549 653 967 1.523 882 27 0 0 0 0 0 0
Totale 11.312